GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Revenue

Invex Therapeutics (ASX:IXC) Revenue : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Revenue?

Invex Therapeutics's revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil. Invex Therapeutics's Revenue per Share for the six months ended in Dec. 2023 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Invex Therapeutics Revenue Historical Data

The historical data trend for Invex Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Revenue Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23
Revenue
- - - -

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Invex Therapeutics's Revenue

For the Biotechnology subindustry, Invex Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invex Therapeutics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Revenue falls into.



Invex Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invex Therapeutics  (ASX:IXC) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Invex Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Invex Therapeutics (ASX:IXC) Business Description

Traded in Other Exchanges
N/A
Address
38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.

Invex Therapeutics (ASX:IXC) Headlines

From GuruFocus

Verger Capital Management LLC Buys iShares Global Energy ETF, iShares Gold Trust

By GuruFocus Research GuruFocus Editor 10-29-2021

Ken Fisher's Top 4th-Quarter Trades

By Graham Griffin Graham Griffin 02-01-2021